Drug Type Trispecific T-cell engager (TriTE) |
Synonyms SHR-9539 |
Target |
Action stimulants |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Myeloma | Phase 1 | China | 24 Jul 2024 | |
| Multiple Myeloma | Phase 1 | China | 24 Jul 2024 |






